Regulatory FDA points to liver injury with Amgen’s Tavneos PharmaphorumThe FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug.RegulatoryImmunology & InflammationRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum The FDA has raised the pressure on Amgen to withdraw vasculitis drug Tavneos from the market with a report linking serious side effects to the drug. RegulatoryImmunology & InflammationRead full story Post navigation Previous: Eli Lilly outlays $7.8bn to acquire sleep drug biotech CentessaNext: Telomir seeks FDA approval for Telomir-1 to treat breast cancer Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026